Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Absci (Nasdaq: ABSI) granted a non-statutory option for 276,200 shares to a newly hired non-executive employee on May 1, 2026 as an inducement under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The option carries an exercise price of $4.92 (closing price on the Grant Date), a 10-year term, and vests 25% after one year with the remaining 75% vesting in approximately equal monthly installments over the following 36 months, subject to continued service and plan terms.

News Market Reaction – ABSI

-0.18%

33 alerts

-0.18% Session close to close

+9.5% Peak in 3 hr 5 min

$880.61M Market Cap

1.0x Rel. Volume

In the May 5 session, ABSI declined 0.18%, reflecting a mild negative market reaction. Argus tracked a peak move of +9.5% during that session. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard inducement equity grant of 276,200 non-statutory stock options ...

Analysis

This announcement details a standard inducement equity grant of 276,200 non-statutory stock options at $4.92 under Absci’s 2023 Inducement Plan, vesting over four years. It follows earlier compensation grants and routine SEC filings outlining significant investment in AI-driven antibody programs. The news highlights ongoing hiring and retention efforts but does not change previously disclosed financials or pipeline timelines. Investors may continue to monitor future earnings, clinical readouts for ABS-201, and any use of the existing shelf registration.

Key Figures

Inducement option size: 276,200 shares Exercise price: $4.92 per share Option term: 10 years +5 more

8 metrics

Inducement option size 276,200 shares Non-statutory option to new non-executive employee

Exercise price $4.92 per share Closing price on Nasdaq Global Select Market on May 1, 2026

Option term 10 years Non-statutory stock option under 2023 Inducement Plan

Vesting schedule 4 years 25% after 1 year, remaining 75% in 36 monthly installments

Shelf registration capacity $400,000,000 Preliminary Form S-3 filed August 12, 2025

ATM component $100,000,000 Common stock sales agreement with TD Securities (USA) LLC

Carried-forward unsold securities $75,175,613 From prior registration statement into current S-3

Pre-shelf share price $2.92 ABSI closing price on August 7, 2025 cited in S-3

Historical Context

5 past events · Latest: Apr 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 23	Earnings call timing	Neutral	-0.8%	Announcement of date and time for Q1 2026 business update call.
Apr 08	Conference participation	Positive	+2.4%	Needham healthcare conference participation with scheduled fireside chat webcast.
Mar 24	Earnings and pipeline	Positive	-3.0%	Q4 and 2025 results plus ABS-201 progress and hair-growth activity data.
Mar 24	Clinical advisory board	Positive	+2.7%	Launch of ABS-201 Endometriosis Advisory Board and Phase 2 planning timelines.
Mar 06	Inducement option grant	Neutral	+5.5%	650,000-share CMO inducement option with four-year vesting at $2.57 strike.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News tied to clinical and strategic updates has often seen positive alignment, while financial reports and administrative items like grants have shown mixed or divergent price reactions.

Recent Company History

Over recent months, Absci has combined clinical progress on lead antibody ABS-201 with routine corporate updates. A March 10-K and 8-K detailed 2025 financials and ongoing losses alongside favorable early safety data and cash of $144.3M. Advisory board formation for ABS-201 in endometriosis and conference participation drew constructive reactions. By contrast, the prior inducement grant on March 6, 2026 coincided with a stronger price move, highlighting how even administrative equity awards can intersect with trading momentum around the name.

Key Terms

non-statutory stock option, nasdaq listing rule 5635(c)(4)

2 terms

non-statutory stock option financial

"granted a non-statutory stock option to purchase an aggregate of 276,200 shares"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option award has an exercise price of $4.92 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on May 1, 2026 the (“Grant Date”). The stock option has a 10-year term and vests over four years, and 25% of the shares subject to the option vest and become exercisable on the one-year anniversary of the Grant Date and the remaining 75% of the shares subject to the option vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to the new employee will be fully vested on the fourth anniversary of the Grant Date, subject to the new employee’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

What did Absci (ABSI) announce on May 5, 2026 about a stock option grant?

Absci announced a non-statutory option for 276,200 shares granted May 1, 2026. According to the company, the award is an inducement under its 2023 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4).

What are the key terms of Absci's (ABSI) inducement option granted May 1, 2026?

The option has an exercise price of $4.92, a 10-year term, and vests over four years. According to the company, 25% vests after one year and the remaining 75% vests in approximately equal monthly installments over 36 months.

Who received the Absci (ABSI) inducement grant and why was it given?

A newly hired non-executive employee received the grant of 276,200 shares. According to the company, the award was made as an inducement material to the employee's acceptance of employment and approved by the compensation committee.

How will Absci's (ABSI) 276,200-share option affect shareholder dilution?

The dilution depends on Absci's total outstanding shares, which the announcement does not disclose. According to the company, the option is subject to exercise pricing and vesting, so actual dilution will occur only if and when options are exercised.

Why was Absci's (ABSI) grant disclosed under Nasdaq Listing Rule 5635(c)(4)?

Because the award is an inducement material to employment, it was authorized under Nasdaq Listing Rule 5635(c)(4). According to the company, the grant was approved by the compensation committee pursuant to the 2023 Inducement Plan.